A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 10,057 shares of CPRX stock, worth $221,957. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,057
Holding current value
$221,957
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$15.19 - $21.35 $152,765 - $214,716
10,057 New
10,057 $199,000
Q1 2023

May 09, 2023

BUY
$14.34 - $21.05 $2.34 Million - $3.43 Million
163,060 Added 545.97%
192,926 $3.2 Million
Q4 2022

Feb 10, 2023

SELL
$12.25 - $19.5 $895,989 - $1.43 Million
-73,142 Reduced 71.01%
29,866 $555,000
Q3 2022

Nov 10, 2022

BUY
$7.06 - $15.52 $727,236 - $1.6 Million
103,008 New
103,008 $1.32 Million
Q2 2022

Aug 05, 2022

SELL
$6.23 - $8.57 $152,205 - $209,373
-24,431 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$5.31 - $8.31 $62,870 - $98,390
-11,840 Reduced 32.64%
24,431 $203,000
Q4 2021

Feb 10, 2022

BUY
$5.21 - $7.45 $188,971 - $270,218
36,271 New
36,271 $246,000
Q2 2020

Aug 13, 2020

SELL
$3.48 - $5.05 $170,694 - $247,702
-49,050 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$2.61 - $5.21 $128,020 - $255,550
49,050 New
49,050 $188,000
Q3 2019

Nov 13, 2019

SELL
$3.89 - $7.43 $55,751 - $106,486
-14,332 Closed
0 $0
Q2 2019

Aug 07, 2019

BUY
$2.7 - $6.11 $38,696 - $87,568
14,332 New
14,332 $55,000
Q1 2019

May 08, 2019

SELL
$2.11 - $5.33 $77,437 - $195,611
-36,700 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$1.92 - $3.62 $10,920 - $20,590
5,688 Added 18.34%
36,700 $70,000
Q3 2018

Nov 13, 2018

BUY
$2.81 - $3.78 $16,893 - $22,725
6,012 Added 24.05%
31,012 $117,000
Q2 2018

Aug 02, 2018

BUY
$2.26 - $3.84 $56,499 - $96,000
25,000 New
25,000 $78,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.27B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.